NASDAQ:CYCC Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis $9.72 -1.49 (-13.29%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$9.60 -0.12 (-1.23%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CYCC alerts:Sign Up Key Stats Today's Range$9.50▼$10.9350-Day Range$0.23▼$26.2552-Week Range$3.08▼$597.60Volume145,070 shsAverage Volume5.39 million shsMarket Capitalization$15.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. Read More Cyclacel Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks5th Percentile Overall ScoreCYCC MarketRank™: Cyclacel Pharmaceuticals scored higher than 5% of companies evaluated by MarketBeat, and ranked 917th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Cyclacel Pharmaceuticals.Read more about Cyclacel Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cyclacel Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cyclacel Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cyclacel Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.79% of the float of Cyclacel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyclacel Pharmaceuticals has recently increased by 9,369.23%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldCyclacel Pharmaceuticals does not currently pay a dividend.Dividend GrowthCyclacel Pharmaceuticals does not have a long track record of dividend growth.Read more about Cyclacel Pharmaceuticals' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.79% of the float of Cyclacel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyclacel Pharmaceuticals has recently increased by 9,369.23%, indicating that investor sentiment is decreasing significantly. News and Social Media1.1 / 5News SentimentN/A News SentimentCyclacel Pharmaceuticals has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cyclacel Pharmaceuticals this week, compared to 1 article on an average week.Search Interest18 people have searched for CYCC on MarketBeat in the last 30 days. This is an increase of 260% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cyclacel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cyclacel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders51.20% of the stock of Cyclacel Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 23.58% of the stock of Cyclacel Pharmaceuticals is held by institutions.Read more about Cyclacel Pharmaceuticals' insider trading history. Receive CYCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CYCC Stock News HeadlinesCYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITYJuly 16, 2025 | finance.yahoo.comCyclacel stock dips after trimming 270% surge amid volatility concernsJuly 16, 2025 | msn.comThis Crypto Is Set to Explode in JanuaryFree summit reveals where Bitcoin goes after $120k Don't miss this rare opportunity to learn directly from the experts who are driving this market…August 2 at 2:00 AM | Crypto 101 Media (Ad)Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?July 15, 2025 | benzinga.comWhy Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?July 15, 2025 | benzinga.comCyclacel Pharmaceuticals, Inc. (CYCCP) - Yahoo FinanceJuly 13, 2025 | finance.yahoo.comCyclacel stock soars after amendment to exchange agreement with FITTERSJuly 7, 2025 | in.investing.comCyclacel Stock Surges 50% After Amending Exchange Agreement with FITTERSJuly 7, 2025 | msn.comSee More Headlines CYCC Stock Analysis - Frequently Asked Questions How have CYCC shares performed this year? Cyclacel Pharmaceuticals' stock was trading at $90.24 on January 1st, 2025. Since then, CYCC stock has decreased by 89.2% and is now trading at $9.72. How were Cyclacel Pharmaceuticals' earnings last quarter? Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) announced its quarterly earnings results on Wednesday, April, 2nd. The biotechnology company reported ($79.20) earnings per share for the quarter, missing the consensus estimate of ($69.60) by $9.60. The biotechnology company earned $0.01 million during the quarter, compared to analysts' expectations of $0.01 million. When did Cyclacel Pharmaceuticals' stock split? Shares of Cyclacel Pharmaceuticals reverse split before market open on Monday, July 7th 2025.The 1-15 reverse split was announced on Wednesday, July 2nd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 3rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Cyclacel Pharmaceuticals? Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cyclacel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclacel Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and Arista Networks (ANET). Company Calendar Last Earnings4/02/2025Today8/02/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CYCC CIK1130166 Webwww.cyclacel.com Phone(908) 517-7330Fax866-271-3466Employees14Year FoundedN/AProfitability EPS (Trailing Twelve Months)($839.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.21 million Net MarginsN/A Pretax Margin-55,535.71% Return on Equity-3,648.09% Return on Assets-155.99% Debt Debt-to-Equity RatioN/A Current Ratio5.60 Quick Ratio5.60 Sales & Book Value Annual Sales$14 thousand Price / Sales1,100.44 Cash FlowN/A Price / Cash FlowN/A Book Value($58.87) per share Price / Book-0.17Miscellaneous Outstanding Shares1,585,000Free Float773,000Market Cap$15.41 million OptionableOptionable Beta0.07 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:CYCC) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.